“Today’s announcement paves the way for another successful year,” said Scott DeWire, Global Head of Business Development & Licensing at Boehringer Ingelheim. “Our partners' innovative spirit, combined with our in-house expertise in translation and scaling, creates a winning formula for developing first-in-class treatments for individuals with conditions that currently have limited or no treatment options.”

In addition, Boehringer reported progress in other partnership pipeline projects:

• As part of a long-term collaboration with Oxford Biotherapeutics that goes back to 2013, an exclusive license to a fourth, novel oncology target has been granted, strengthening Boehringer’s T-cell engager and antibody platforms.
• Together with Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), Boehringer reached a first pre-clinical milestone in the development of siRNA based treatments for metabolic dysfunction-associated steatohepatitis (MASH), less than a year after initiation of the partnership. 
• The anti-SIRPα compound BI 770371, developed in partnership with OSE Immunotherapeutics and currently in Phase I in immuno-oncology, will now be tested in a Phase II study in people with liver cirrhosis caused by MASH.

Why it matters

• In 2024, Boehringer Ingelheim significantly bolstered its pipeline through new partnerships across all its therapeutic areas, including oncology and cardio-renal-metabolic (CRM) diseases.
• Deals included a cancer antigen discovery deal with 3T Biosciences and a partnership with Circle Pharma to develop treatments that halt the growth of cancer cells.
• Boehringer also secured access to novel small molecules acting as immune checkpoint inhibitors through the acquisition of Nerio Therapeutics and it signed a long-term translational medicine collaboration with CBmed.
• In addition, the company initiated partnerships with Ochre Bio in liver diseases, and with Ribocure in MASH. 
• In Mental Health, Boehringer entered new partnerships with Sosei Heptares (now Nxera Pharma) and the Broad Institute of MIT and Harvard to develop treatments that improve patient outcomes in mental health conditions.

More info

• Our research pipeline Human Pharma Clinical Pipeline | Boehringer Ingelheim
• Our Focus Science Focus | Boehringer Ingelheim
• Link to Ribocure press release HERE
• Link to Oxford BioTherapeutics press release HERE

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com.